Stage-Based Management of Type 2 Diabetes Mellitus with Heart Failure

Patricia Mejia Osuna; Spandana J. Brown; Laila S. Tabatabai; Dale J. Hamilton

doi:10.14797/mdcj-14-4-257

Stage-Based Management of Type 2 Diabetes Mellitus with Heart Failure

Methodist DeBakey Cardiovascular Journal

Volume 14 (2018): Issue 4

By: Patricia Mejia Osuna, Spandana J. Brown, Laila S. Tabatabai and Dale J. Hamilton

Open Access

|Oct 2018

Abstract

Type 2 diabetes negatively impacts heart failure outcomes. Insulin resistance, central adiposity, dyslipidemia, and altered cellular substrate metabolism each have a mechanistic role. Management strategies focused solely on glycemic control have had limited success. However, three new classes of drugs, each with several options, offer the promise of improved diabetes management in heart failure. Unlike earlier classes, these medications have had favorable cardiovascular outcomes. In this review, we present a therapeutic guide for metabolic treatment based on the stages of heart failure.

References

Kannel WB McGee DL Diabetes and cardiovascular disease. The Framingham study JAMA 1979 May 11 241 19 2035 8
Search in Google Scholar Back to article
Stratton IM Adler AI Neil HA Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study BMJ 2000 Aug 12 321 7258 405 12
Search in Google Scholar Back to article
Nichols GA Gullion CM Koro CE Ephross SA Brown JB The incidence of congestive heart failure in type 2 diabetes: an update Diabetes Care 2004 Aug 27 8 1879 84
Search in Google Scholar Back to article
Greenberg BH Abraham WT Albert NM Influence of diabetes on characteristics and outcomes in patients hospitalized with heart failure: a report from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF) Am Heart J 2007 Aug 154 2 277.e1 8
Search in Google Scholar Back to article
Tenenbaum A Motro M Fisman EZ Functional class in patients with heart failure is associated with the development of diabetes Am J Med 2003 Mar 114 4 271 5
Search in Google Scholar Back to article
Boudina S Abel ED Diabetic cardiomyopathy revisited Circulation 2007 Jun 26 115 25 3213 23
Search in Google Scholar Back to article
Ashrafian H Frenneaux MP Opie LH Metabolic mechanisms in heart failure Circulation 2007 Jul 24 116 4 434 48
Search in Google Scholar Back to article
Boudina S Abel ED Diabetic cardiomyopathy, causes and effects Rev Endocr Metab Disord 2010 Mar 11 1 31 9
Search in Google Scholar Back to article
Tzoulaki I Molokhia M Curcin V Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database BMJ 2009 Dec 3 339 b4731
Search in Google Scholar Back to article
Gilbert RE Krum H Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy Lancet 2015 May 23 385 9982 2107 17
Search in Google Scholar Back to article
Nesto RW Bell D Bonow RO American Heart Association; American Diabetes Association Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003 Circulation 2003 Dec 9 108 23 2941 8
Search in Google Scholar Back to article
Eurich DT Majumdar SR McAlister FA Tsuyuki RT Johnson JA Improved clinical outcomes associated with metformin in patients with diabetes and heart failure Diabetes Care 2005 Oct 28 10 2345 51
Search in Google Scholar Back to article
Smooke S Horwich TB Fonarow GC Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure Am Heart J 2005 Jan 149 1 168 74
Search in Google Scholar Back to article
Pocock SJ Wang D Pfeffer MA Predictors of mortality and morbidity in patients with chronic heart failure Eur Heart J 2006 Jan 27 1 65 75 Epub 2005 Oct 11
Search in Google Scholar Back to article
Koliaki C Doupis J Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus Diabetes Ther 2011 May 2 2 101 21
Search in Google Scholar Back to article
Baggio LL Drucker DJ Biology of incretins: GLP-1 and GIP Gastroenterology 2007 May 132 6 2131 57
Search in Google Scholar Back to article
Grieve DJ Cassidy RS Green BD Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control? Br J Pharmacol 2009 Aug 157 8 1340 51
Search in Google Scholar Back to article
Nikolaidis LA Elahi D Hentosz T Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy Circulation 2004 Aug 24 110 8 955 61
Search in Google Scholar Back to article
Veitenhansl M Stegner K Hierl FX 40th EASD Annual Meeting of the European Association for the Study of Diabetes: Munich, Germany, 5–9 September 2004 Diabetologia 2004 Aug 47 Suppl 1 A1 A464
Search in Google Scholar Back to article
Standl E Schnell O McGuire DK Heart Failure Considerations of Anti-hyperglycemic Medications for Type 2 Diabetes Circ Res 2016 May 27 118 11 1830 43
Search in Google Scholar Back to article
White WB Baker WL Cardiovascular Effects of Incretin-Based Therapies Annu Rev Med 2016 67 245 60
Search in Google Scholar Back to article
Pabreja K Mohd MA Koole C Wootten D Furness SG Molecular mechanisms underlying physiological and receptor pleiotropic effects mediated by GLP-1R activation Br J Pharmacol 2014 Mar 171 5 1114 28
Search in Google Scholar Back to article
Nauck M Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors Diabetes Obes Metab 2016 Mar 18 3 203 16
Search in Google Scholar Back to article
Heerspink HJ Perkins BA Fitchett DH Husain M Cherney DZ Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications Circulation 2016 Sep 6 134 10 752 72
Search in Google Scholar Back to article
Vrhovac I Balen Eror D Klessen D Localizations of Na(+)-D-glucose cotransporters SGLT1 and SGLT2 in human kidney and of SGLT1 in human small intestine, liver, lung, and heart Pflugers Arch 2015 Sep 467 9 1881 98
Search in Google Scholar Back to article
Chilton R Tikkanen I Cannon CP Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes Diabetes Obes Metab 2015 Dec 17 12 1180 93
Search in Google Scholar Back to article
Kaplan A Abidi E El-Yazbi A Eid A Booz GW Zouein FA Direct cardiovascular impact of SGLT2 inhibitors: mechanisms and effects Heart Fail Rev 2018 May 23 3 419 37
Search in Google Scholar Back to article
Mudaliar S Alloju S Henry RR Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis Diabetes Care 2016 Jul 39 7 1115 22
Search in Google Scholar Back to article
Secrest MH Udell JA Filion KB The cardiovascular safety trials of DPP-4 inhibitors, GLP-1 agonists, and SGLT2 inhibitors Trends Cardiovasc Med 2017 Apr 27 3 194 202
Search in Google Scholar Back to article
Martens P Mathieu C Verbrugge FH Promise of SGLT2 Inhibitors in Heart Failure: Diabetes and Beyond Curr Treat Options Cardiovasc Med 2017 Mar 19 3 23
Search in Google Scholar Back to article
Garber AJ Abrahamson MJ Barzilay JI Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm - 2018 Executive Summary Endocr Pract 2018 Jan 24 1 91 120
Search in Google Scholar Back to article
Scirica BM Bhatt DL Braunwald E SAVOR-TIMI 53 Steering Committee and Investigators Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus N Engl J Med 2013 Oct 3 369 14 1317 26
Search in Google Scholar Back to article
White WB Cannon CP Heller SR EXAMINE Investigators Alogliptin after acute coronary syndrome in patients with type 2 diabetes N Engl J Med 2013 Oct 3 369 14 1327 35
Search in Google Scholar Back to article
Green JB Bethel MA Armstrong PW TECOS Study Group Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes N Engl J Med 2015 Jul 16 373 3 232 42
Search in Google Scholar Back to article
Pfeffer MA Claggett B Diaz R ELIXA Investigators Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome N Engl J Med 2015 Dec 3 373 23 2247 57
Search in Google Scholar Back to article
Marso SP Daniels GH Brown-Frandsen K LEADER Steering Committee; LEADER Trial Investigators Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes N Engl J Med 2016 Jul 28 375 4 311 22
Search in Google Scholar Back to article
Marso SP Bain SC Consoli A Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes N Engl J Med 2016 Nov 10 375 19 1834 44
Search in Google Scholar Back to article
Zinman B Wanner C Lachin JM EMPA-REG OUTCOME Investigators Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes N Engl J Med 2015 Nov 26 373 22 2117 28
Search in Google Scholar Back to article
Friedrich EB Böhm M Management of end stage heart failure Heart 2007 May 93 5 626 31
Search in Google Scholar Back to article
Huang ES Management of diabetes mellitus in older people with comorbidities BMJ 2016 Jun 15 353 i2200
Search in Google Scholar Back to article

Articles in this issue

DOI: https://doi.org/10.14797/mdcj-14-4-257 | Journal eISSN: 1947-6108

Journal RSS Feed

Language: English

Page range: 257 - 265

Published on: Oct 1, 2018

Published by: Houston Methodist DeBakey Heart & Vascular Center

In partnership with: Paradigm Publishing Services

Keywords:

© 2018 Patricia Mejia Osuna, Spandana J. Brown, Laila S. Tabatabai, Dale J. Hamilton, published by Houston Methodist DeBakey Heart & Vascular Center
This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 License.

Volume 14 (2018): Issue 4